FTSE MIB
33.629,21 -107,19 (-0,32%) Dow Jones
38.675,68 +450,02 (+1,18%) Nasdaq
16.156,33 +315,37 (+1,99%) Nikkei 225
38.236,07 -37,98 (-0,10%) Petrolio
77,99 -0,96 (-1,22%) Bitcoin EUR
59.137,18 -319,74 (-0,54%)
Vera Therapeutics, Inc. (VERA)
Dopo ore:
| Chiusura precedente | 43,50 |
| Aperto | 44,96 |
| Denaro | 43,38 x 400 |
| Lettera | 43,48 x 300 |
| Min-Max giorno | 43,41 - 45,48 |
| Intervallo di 52 settimane | 7,10 - 50,78 |
| Volume | |
| Media Volume | 1.065.826 |
| Capitalizzazione | 2,365B |
| Beta (5 anni mensile) | 1,05 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -2,25 |
| Prossima data utili | 09 mag 2024 - 13 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 48,88 |
GlobeNewswireVera Therapeutics to Present Three Posters at the American Society of Nephrology Kidney Week 2023 Annual Meeting
Informational poster for ORIGIN 3 Pivotal Phase 3 study evaluating atacicept in IgA Nephropathy (IgAN) Additional analysis of week 36 data from Phase 2b ORIGIN study show atacicept 150mg reduces serum Gd-IgA1, supporting atacicept’s potential as long-term disease-modifying IgAN therapy Atacicept showed continued protective titers to diphtheria and tetanus and balanced COVID infections vs. placebo in IgAN BRISBANE, Calif., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA),
- GlobeNewswire
Vera Therapeutics Scheduled to Present at September Investor Conferences
BRISBANE, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will present and participate in one-on-one meetings at four investor conferences being held next month. Investor Conference Details: Citi 18th Annual BioPharma ConferenceFormat: Management hostin
- GlobeNewswire
Vera Therapeutics Provides Business Update and Reports Second Quarter Financial Results
Presented positive 36-week results from the Phase 2b ORIGIN clinical trial of atacicept in IgAN as a late breaking clinical trial at the 60th ERA CongressInitiated Phase 3 ORIGIN 3 clinical trial of atacicept in June for the treatment of IgANStrong balance sheet expected to fund operations to early 2026 BRISBANE, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative tr
